An analyst at Deutsche Bank recently referenced a drug as a threat to Eli Lilly's competing treatment.Over the last couple of years, one of the biggest stories in the stock market has been around pharmaceutical companies that are thriving due to the proliferation of their weight loss drug treatments.
Due to this, many are paying close attention to which company will be next to develop a new and hopefully improved weight-loss drug that can lead to similar stock price success.One interesting distinction in the weight loss drug landscape is that of injectable drugs versus oral drugs. Lilly and Novo currently deliver their drugs Zepbound and Wevogy, via self-injections. However, research at these and other firms is working to develop weight loss treatments as a once-daily oral pill.
These results are encouraging but also lead to significant questions. First, the company only released data after four weeks. This is a very short time frame; data for orforglipron is available for up to 36 weeks. However, it is from a Phase 2 trial, so that is to be expected. The CT-988 results were reportedly only based on the testing from six patients, a very low sample size.
المملكة العربية السعودية أحدث الأخبار, المملكة العربية السعودية عناوين
Similar News:يمكنك أيضًا قراءة قصص إخبارية مشابهة لهذه التي قمنا بجمعها من مصادر إخبارية أخرى.
مصدر: wrtv - 🏆 598. / 51 اقرأ أكثر »